Asset Details
Do you wish to reserve the book?
ARRONAX, a high-energy and high-intensity cyclotron for nuclear medicine
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
ARRONAX, a high-energy and high-intensity cyclotron for nuclear medicine
Do you wish to request the book?
ARRONAX, a high-energy and high-intensity cyclotron for nuclear medicine
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
ARRONAX, a high-energy and high-intensity cyclotron for nuclear medicine
2008
Overview
Purpose
This study was aimed at establishing a list of radionuclides of interest for nuclear medicine that can be produced in a high-intensity and high-energy cyclotron.
Methods
We have considered both therapeutic and positron emission tomography radionuclides that can be produced using a high-energy and a high-intensity cyclotron such as ARRONAX, which will be operating in Nantes (France) by the end of 2008. Novel radionuclides or radionuclides of current limited availability have been selected according to the following criteria: emission of positrons, low-energy beta or alpha particles, stable or short half-life daughters, half-life between 3 h and 10 days or generator-produced, favourable dosimetry, production from stable isotopes with reasonable cross sections.
Results
Three radionuclides appear well suited to targeted radionuclide therapy using beta (
67
Cu,
47
Sc) or alpha (
211
At) particles. Positron emitters allowing dosimetry studies prior to radionuclide therapy (
64
Cu,
124
I,
44
Sc), or that can be generator-produced (
82
Rb,
68
Ga) or providing the opportunity of a new imaging modality (
44
Sc) are considered to have a great interest at short term whereas
86
Y,
52
Fe,
55
Co,
76
Br or
89
Zr are considered to have a potential interest at middle term.
Conclusions
Several radionuclides not currently used in routine nuclear medicine or not available in sufficient amount for clinical research have been selected for future production. High-energy, high-intensity cyclotrons are necessary to produce some of the selected radionuclides and make possible future clinical developments in nuclear medicine. Associated with appropriate carriers, these radionuclides will respond to a maximum of unmet clinical needs.
Publisher
Springer-Verlag,Springer Nature B.V,Springer Verlag (Germany) [1976-....]
Subject
Alpha Particles - therapeutic use
/ Beta Particles - therapeutic use
/ Cyclotrons - instrumentation
/ France
/ High Energy Physics - Experiment
/ Humans
/ Imaging
/ Medicine
/ Nuclear Medicine - instrumentation
/ Nuclear Physics - instrumentation
/ Oncology
/ Physics
/ Positron-Emission Tomography
/ Radioisotopes - isolation & purification
/ Radioisotopes - therapeutic use
/ Radiopharmaceuticals - isolation & purification
